Validation of Histoplasmosis Enzyme Immunoassay to Evaluate Suspicious Lung Nodules

Shipe, Maren E.; Deppen, Stephen A.; Sullivan, Shelbi; Kammer, Michael N.; Starnes, Sandra L.; Wilson, David O.; Massion, Pierre P.; Grogan, Eric L.

doi:10.1016/j.athoracsur.2020.05.101

Cited by 11 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, patients with indeterminate pulmonary nodules in endemic areas can be benefited from the use of histoplasma IgG and IgM antibodies measured using EIA testing, and these antibodies potentially decrease unnecessary invasive biopsies for the diagnosis of chronic histoplasmosis [18].…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Histoplasmosis in a Referral Hospital in Mexico City

Solís

Santibáñez

Olán

et al. 2022

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

Pulmonary histoplasmosis is caused by inhaling Histoplasma capsulatum. Less than 1% develops the disease. Risk factors in immunocompetent individuals are environmental exposures in endemic areas. The objective of this study is to determine the frequency, clinical, and microbiological characteristics in immunocompetent patients. A retrospective case series study of patients diagnosed with pulmonary histoplasmosis was performed in a respiratory care unit in Mexico City from 2000 to 2020. Each patient had bronchial lavage, and three patients underwent thoracoscopy for the lung tissue sample taken for the culture in Sabouraud Dextrose Agar. Twelve patients were identified, 8 males and 4 females; the predominant symptoms were fever (83%), dyspnea (75%), chest pain (66%), hemoptysis (41%), and weight loss (33%). The computed tomography of the chest showed the following findings: patchy consolidation 12 (100%), hilar adenopathy 6 (50%), pleural effusion 6 (50%), caverns 3 (25%), and solitary pulmonary nodule in one patient (8%). Histoplasma capsulatum was found in the culture of all twelve patients. The signs and symptoms of the disease are mediated by the immune status of the host. The clinical picture is often confused with systemic diseases. It is important to have a high degree of clinical suspicion to make a timely diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Pulmonary Histoplasmosis in a Referral Hospital in Mexico City

Solís

Santibáñez

Olán

et al. 2022

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

show abstract

“…Furthermore, biostatistical help with analyses is frequently provided to EDRN collaborative sites to ensure that methodological rigor is achieved. The Phase III studies that have used VUMC samples, infrastructure and expertise have advanced the study of many of the most promising biomarkers [14,15,18,19,[24][25][26][27][28][29]. The VUMC EDRN Lung CVC has provided samples for the majority of published Phase III studies at some point in their development and validation within the context of indeterminate pulmonary nodule evaluation.…”

Section: Biomarker Validationmentioning

confidence: 99%

The impact of the lung EDRN-CVC on Phase 1, 2, & 3 biomarker validation studies

Kammer

Deppen

Antic

et al. 2022

CBM

Self Cite

View full text Add to dashboard Cite

The Early Detection Research Network’s (EDRN) purpose is to discover, develop and validate biomarkers and imaging methods to detect early-stage cancers or at-risk individuals. The EDRN is composed of sites that fall into four categories: Biomarker Developmental Laboratories (BDL), Biomarker Reference Laboratories (BRL), Clinical Validation Centers (CVC) and Data Management and Coordinating Centers. Each component has a crucial role to play within the mission of the EDRN. The primary role of the CVCs is to support biomarker developers through validation trials on promising biomarkers discovered by both EDRN and non-EDRN investigators. The second round of funding for the EDRN Lung CVC at Vanderbilt University Medical Center (VUMC) was funded in October 2016 and we intended to accomplish the three missions of the CVCs: To conduct innovative research on the validation of candidate biomarkers for early cancer detection and risk assessment of lung cancer in an observational study; to compare biomarker performance; and to serve as a resource center for collaborative research within the Network and partner with established EDRN BDLs and BRLs, new laboratories and industry partners. This report outlines the impact of the VUMC EDRN Lung CVC and describes the role in promoting and validating biological and imaging biomarkers.

show abstract